Eli Lilly announces $1 billion investment to set up major facility in Hyderabad

US pharmaceutical giant Eli Lilly and Company has announced plans to invest over $1 billion in India over.

The next few years, marking one of its largest commitments in the country to date. The move aims to bolster its manufacturing capacity and strengthen global supply chains for key medicines.

The investment will include the establishment of a new Manufacturing and Quality hub in Hyderabad, which will serve as a central node for overseeing production and quality operations across India. Lilly will also collaborate with local contract manufacturers to expand its footprint in the country’s thriving pharmaceutical ecosystem.

Hiring for the Hyderabad facility will begin immediately, with openings for engineers, chemists, analytical scientists, and quality professionals. The company said the hub will integrate into its global manufacturing network, ensuring reliable supply of treatments for diabetes, obesity, Alzheimer’s, cancer, and autoimmune diseases.

Patrik Jonsson, President of Lilly International, said the investment underscores India’s growing importance in the company’s global operations. “We are making strategic investments to expand manufacturing and supply capacity worldwide. India will play a crucial role in supporting our future portfolio,” he said.

The announcement follows Lilly’s launch of its blockbuster diabetes and weight-loss drug Mounjaro in India earlier this year. With rising global demand for obesity treatments, analysts say the investment will help Lilly secure long-term supply and maintain a competitive edge in the fast-expanding therapeutic segment.

Telangana Chief Minister A. Revanth Reddy hailed the investment as a testament to Hyderabad’s emergence as a leading global healthcare hub. Industries Minister D. Sridhar Babu highlighted the state’s focus on innovation-driven growth and its pro-industry policies that attract multinational investors.

Invest India CEO Nivruti Rai said Lilly’s plan reinforces India’s position as a global manufacturing powerhouse for pharmaceuticals.

Since 2020, Lilly has announced over $55 billion in global manufacturing investments, including major projects in the United States. The India expansion, analysts say, cements the country’s position as a key link in Lilly’s global production network and reflects growing confidence in India’s life sciences capabilities.